RECRUITING

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Description

Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.

Conditions

Study Overview

Study Details

Study overview

Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.

Comparison of I-124 PET/CT to I-123 Whole Body Imaging for the Diagnosis of Thyroid

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Condition
Thyroid Cancer
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94122

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age \>= 18 years.
  • 2. Histopathologically confirmed differentiated thyroid cancer, with clinical concern for metastatic disease, which is based on:
  • 1. Metastatic disease seen on I-123 SPECT, Fluorodeoxyglucose (FDG) PET, CT scan or ultrasound.
  • 2. Elevated thyroglobulin in participant after total thyroidectomy.
  • 3. Planned I-123 imaging within 45 days after enrollment.
  • 4. Ability to understand a written informed consent document, and the willingness to sign it.
  • 1. Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
  • 2. Known pregnancy, per institutional policy.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Thomas Hope,

Thomas Hope, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2026-03-31